Biotech Firms Pivoted to In Vivo Cell Therapies
ArsenalBio and TScan Therapeutics redirected clinical development to internal delivery methods amid cost-cutting measures.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize long-term patient health over shifting their financial research strategies?
On August 31 and September 2, 2026, ArsenalBio and TScan Therapeutics announced strategic shifts toward in vivo cell therapy programs. Both companies reduced their workforces to realign development resources.
Why it matters
The transition reflects a growing industry effort to engineer immune cells directly within the patient rather than ex vivo, a move intended to bypass the operational complexities of traditional cell therapies. The shift follows capital constraints that forced companies to narrow their pipelines.
TScan Therapeutics paused enrollment in its Phase 3 ALLOHA-2 study due to insufficient capital. The company redirected remaining resources toward in vivo TCR-T candidates targeting PRAME and MAGE-A4 proteins in solid tumors.
The players
ArsenalBio
A biotechnology company specializing in engineered cell therapies for cancer and autoimmune conditions.
TScan Therapeutics
A developer of T-cell receptor-based therapies currently pivoting from ex vivo to in vivo approaches.
The details
In vivo cell therapy involves engineering immune cells inside the patient, contrasting with ex vivo methods where cells are extracted and modified in a laboratory before reinfusion. By targeting proteins like PRAME and MAGE-A4—specific antigens expressed on the surface of solid tumors—these programs attempt to simplify delivery and production. ArsenalBio is applying this focus to hematologic malignancies and autoimmune diseases as part of its strategic realignment.
Timeline
August 31, 2026: ArsenalBio announced its strategic shift and workforce reduction.
September 2, 2026: TScan Therapeutics paused trial enrollment and executed a workforce cut.
The Tech Race
This pivot follows a pattern of pipeline prioritization in the cell therapy sector, marked by the abandonment of the Phase 3 ALLOHA-2 study. It signals a move away from late-stage ex vivo trials to preserve capital for in vivo research and development.
The suspension of the ALLOHA-2 study immediately impacts clinical trial participants who were eligible for the TSC-101 therapy. Future availability of new in vivo treatments remains dependent on these firms successfully completing their restructured research and development programs.
The takeaway
The pivot toward in vivo platforms marks a shift in how firms approach cell therapy scalability. Watch for upcoming clinical progress reports from both companies as they attempt to validate these new therapeutic targets.
Further reading
For more on the evolving field of cell engineering, visit Biotech.
Source note: This article includes information reported by BioPharm International.
Live Poll
Do you trust pharmaceutical companies to prioritize long-term patient health over shifting their financial research strategies?
